Abstract
Recombinant human liver UDP-glucuronosyltransferase (UGT), UGT1*6, which catalyzes the glucuronidation of small phenols, previously expressed in a V79 cell line (1) was photolabeled with [β-32P]5N3UDP-glucuronic acid ([β-32P]5N3UDP-GlcUA). Two polypeptides with an approximate molecular weight of 54 kDa were extensively photolabeled in the recombinant cell line while the nontransfected cell line showed no photoincorporation in this area. The identity of the two polypeptides as UGTs, which correspond to two different glycosylation forms of the same enzyme, was confirmed by Western blot using a polyclonal monospecific antibody directed against the 120 amino acids of the N-terminal end of UGT1*6. Preincubation with UDP-glucuronic acid (UDP-GlcUA) inhibited the photoincorporation of the probe into the polypeptides indicating competition of both the photoprobe and the nucleotide-sugar for the same binding site. It was further shown that photoincorporation of [β-32P]5N3UDP-GlcUA into the UDP-GlcUA-binding site was saturable. The lack of photoincorporation of a related photoprobe, [β-32P]5N3UDP-glucose ([β-32P]5N3UDP-Glc), into UGT1*6 demonstrated specificity of this enzyme for UDP-GlcUA. In enzymatic assays, unlabeled 5N3UDP-GlcUA was shown to be an effective cosubstrate of the glucuronidation of 4-nitrophenol catalyzed by UGT1*6. The studies were further extended by demonstrating that photolabeling of UGT1*6 was inhibited by several active site-directed inhibitors. Finally, photoaffinity labeling was used in the purification of the labeled UGT1*6 using preparative gel electrophoresis. In conclusion, we have demonstrated that photoaffinity labeling with [β-32P]5N3UDP-GlcUA is an effective tool for the characterization of enzymes such as recombinant UGTs that use UDP-GlcUA.
Footnotes
-
Send reprint requests to: Anna Radominska, Division of Gastroenterology, University of Arkansas for Medical Sciences, 4301 W. Markham, slot 567–1, Little Rock, Arkansas 72205
-
This work was supported in part by a NIH grant DK-38678 (AR) and DK-45123 (AR).
-
↵2 T. Pillot, S. Fournel-Gigleux, and J. Magdalou, unpublished observations.
- Abbreviations used are::
- [β-32P]5-N3 UDP-GlcUA
- [β-32P]5-azido-UDP-glucuronic acid
- [β-32P]5-N3 UDP-Glc
- [β-32P]5-azido-UDP-glucose
- UDP-GlcUA
- UDP-glucuronic acid
- GPDS
- UDP-glucose:dolichylphosphate glycosyltransferase, 4-MU, 4-methylumbelliferone
- SDS
- sodium dodecyl sulfate
- TCA
- trichloroacetic acid
- PP36 (DHPGAdU)
- 5′-[[N-(2-decanoylamino-3-hydroxy-3-phenyl-propyloxycarbonyl)glycyl]amino]-5′-deoxyuridine
- PP37P (DHPASiU)
- 5′-O-[[(2-decanoylamino-3-hydroxy-3-phenyl-propyloxycarbonyl)amino]sulfonyl]-2′,3′-O-isopropylideneuridine
- PP37 (DHPASU)
- 5′-O-[[(2-decanoylamino-3-hydroxy-3-phenyl-propyloxycarbonyl)amino]sulfonyl]uridine
- PP50 (DPASiU)
- 5′-O-[[(2-decanoylamino-3-phenyl-propyloxycarbonyl)amino]sulfonyl]-2′,3′-O-isopropylideneuridine
- PP55 (DPASU)
- 5′-O-[[(2-decanoylamino-3-phenyl-propyloxycarbonyl)amino]sulfonyl]uridine
- PP56B (D-DPMSU)
- 5′-O-[[(2-decanoyl-3-phenyl-propyloxycarbonyl)methylsulfonyl] uridine
- Received July 19, 1996.
- Accepted January 7, 1997.
- The American Society for Pharmacology and Experimental Therapeutics
DMD articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|